General
Preferred name
GEMFIBROZIL
Synonyms
CI-719 ()
Lopid ()
Jezil ()
Decrelip ()
Gemfibrozil (Lopid) ()
GEMFIBROZIL25812-30-0 ()
Emfib ()
NSC-757024 ()
Gemfibrozil-d6 ()
P&D ID
PD002321
CAS
25812-30-0
114413-98-8
1184986-45-5
Tags
natural product
drug
available
Approved by
FDA
First approval
1981
Drug Status
approved
Drug indication
Antihyperlipidemic
Hyperlipidaemia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Gemfibrozil activates peroxisome proliferator-activated receptor alpha (PPARα) transcription factor ligand. This receptor is involved in the metabolism of carbohydrates and fats, as well as the differentiation of adipose tissue. Activation of this receptor increases extrahepatic lipoprotein lipase, and therefore lipoprotein triglyceride lipolysis. This increases the clearance of triglycerides. Increase triglyceride clearance leads to degradation of chylomicrons, VLDL conversion to LDL, LDL conversion to HDL, and increase secretion of lipids into bile in the intestine. Gemfibrozil also inhibits synthesis and increases clearance of apolipoprotein B which carries VLDL.
DESCRIPTION Gemfibrozil is a fibric acid antilipemic agent, pharmacologically similar to clofibrate. (GtoPdb)
DESCRIPTION Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
33
AdooQ Bioactive Compound Library
A10424
BOC Sciences Bioactive Compounds
gemfibrozil-cas-25812-30-0-item-84-88721
Cayman Chemical Bioactives
14835
31915
ChEMBL Approved Drugs
CHEMBL457
ChEMBL Drugs
CHEMBL457
Concise Guide to Pharmacology 2017/18
3439
Concise Guide to Pharmacology 2019/20
3439
Concise Guide to Pharmacology 2021/22
3439
Concise Guide to Pharmacology 2023/24
3439
Drug Repurposing Hub
DrugBank
DB01241
DrugBank Approved Drugs
DB01241
DrugCentral
1285
DrugCentral Approved Drugs
1285
DrugMAP
DMD8Q3J
DrugMAP Approved Drugs
DMD8Q3J
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101169
Guide to Pharmacology
3439
Mcule NIBR MoA Box Subset
MCULE-4563546953
MedChem Express Bioactive Compound Library
HY-B0258
NCATS Inxight Approved Drugs
Q8X02027X3
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2F78D22792E0
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Gemfibrozil(Lopid)
TargetMol Bioactive Compound Library
T1415
The Spectrum Collection
ZINC Tool Compounds
ZINC000001530641
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
250.16
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
1
cLogP
3.57
TPSA
46.53
Fraction CSP3
0.53
Chiral centers
0.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
GPCR/G protein
DNA Damage/DNA Repair
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Target
PPAR??
CYP2C9
1A2
LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1
Cytochrome P450
PPAR
Member status
member
MOA
PPARalpha Agonists
lipoprotein lipase activator
Indication
hyperlipidemia, coronary heart disease
Disease Area
endocrinology, cardiology
Therapeutic Class
Antilipemic Agents
Source data